A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs Nelipepimut-S (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Phio Pharmaceuticals; RXi Pharmaceuticals
- 17 May 2018 According to a Sellas Life Sciences Group media release, the company will be conducting clinical and regulatory advisory board meetings at ASCO on May 30 and May 31 2018, based on the independent Data Safety Monitoring Board recommendation to seek regulatory guidance by the FDA.
- 30 May 2014 New trial record
- 06 Jun 2011 According to a RXi Pharmaceuticals media release, data presented at the American Society of Clinical Oncology (ASCO).